A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Inclusion Criteria

• •Participant has histologically confirmed Grade 1, 2 or 3a follicular lymphoma (FL) or classic FL. Formalin-fixed paraffin embedded (FFPE) archival tissue from 1 year prior to screening is allowed. If more than 1 year has passed, then a fresh biopsy must be obtained to confirm the diagnosis.
• •Have no prior systemic treatment for follicular lymphoma. Prior radiation therapy or surgery for previously diagnosed stage I disease is acceptable.
• •Stage II to IV disease.
• •Deemed to need treatment by treating investigator. Reasons for treatment can include, but are not limited to, the following:.
• •i) Bulky disease defined as:.
• •A. A nodal or extra nodal (except spleen) mass \> 7cm in its greater diameter or, involvement of at least 3 nodal or extra nodal sites (each with a diameter greater than \>3 cm).
• •ii) Presence of at least one of the following B symptoms:.
• •A. Fever (\>38°C) of unclear etiology.
• •B. Night sweats.
• •C. Weight loss greater than 10% within the prior 6 months.
• •iii) Splenomegaly with inferior margin below the umbilical line.
• •iv) Any one of the following cytopenia due to lymphoma:.
• •A. Platelets \<100,000 cells/mm3 (100 x 109/L).
• •B. Absolute neutrophil count (ANC) \< 1,000 cells/mm3 (1.0 x 109/L).
• •C. Hemoglobin \< 10g/dL (6.25 mmol/L).
• •v) Pleural or peritoneal serous effusion (irrespective of cell content).
• •vi) Any compressive syndrome (for example, but not restricted to ureteral, orbital, gastrointestinal).